Lancet ID Commentary to the G20 on behalf of the DRIVE-AB Steering Committee

I am pleased to say that a commentary to the G20 on behalf of the DRIVE-AB Steering Committee has now gone live in the Online First section of Lancet Infectious Diseases. The article is not Open Access so you’ll have to download it for yourself (link below).

The commentary summarises some of DRIVE-AB’s preliminary findings that are pertinent to the G20 discussions as this list of recommendations:

  • Immediately fill the gap of US$250 million per year in push funding; existing mechanisms require additional financing and are well suited for an immediate in-flow of extra financing
  • Implement market entry reward pilots to learn about the operationalisation of such models
  • Request that regional and global banking institutions (such as the European Investment Bank and the World Bank) examine potential novel financial instruments to support further antibacterial R&D funding
  • Establish a mechanism for multinational coordination and collaboration
  • Develop health technology assessment processes and rules of reimbursement to consider the resistance situation and capture antibiotic societal value

DRIVE-AB’s complete findings will be published and presented at the DRIVE-AB conference in Brussels on Sept 5–6, 2017. 

Best wishes and stayed tuned for further developments! –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust | Follow me on Twitter: @JohnRex_NewAbx

Upcoming events of note outside of the mainstream large meetings:

  • 10-11 July: FDA workshop on bacteriophage therapies
  • 19 July: FDA workshop on combination therapy for TB
  • 5-9 Sep: ASM-ESCMID conference on antibiotic R&D, including the CARB-X + GARDP Antibiotic Bootcamp
  • 13 Sep 2017 (DC): FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance

Link to online article: http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30404-8/abstract

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top